Alegre M L, Sattar H A, Herold K C, Smith J, Tepper M A, Bluestone J A
Department of Medicine, University of Chicago, Illnois 60637.
Transplantation. 1994 Jun 27;57(12):1786-94.
Multiple treatments with the potent immunosuppressant murine antihuman CD3 mAb OKT3 is sometimes precluded by the onset of a neutralizing humoral response mostly consisting of anti-idiotypic antibodies. A hamster antimurine CD3 monoclonal Ab, 145-2C11, shares many properties with OKT3, in particular the ability to induce a strong Ab response in mice. Deoxyspergulain (DSG), a metabolite of the antibiotic spergualin, has been shown to reduce Ab production triggered by pathogens in a variety of infectious models and against common antigens. In this study, we examined the ability of DSG to inhibit the humoral response induced by 145-2C11. DSG prevented the Ab production triggered by the anti-CD3 mAb in an Ag-specific manner and significantly reduced the Ab production in mice previously primed with 145-2C11. We showed that DSG had a long-term effect on B cells and a transient effect on T cells. In effect, DSG was found to induce a prolonged Ag-specific unresponsiveness of B lymphocytes, and to transiently reduce the capacity of T lymphocytes to deliver help to B cells, in part by reducing IL-4 production. DSG did not reduce the immunosuppressive properties of the anti-CD3 mAb. In fact, the combination of DSG with 145-2C11 prolonged the survival of allogeneic skin grafts when compared with the administration of 145-2C11 or DSG alone. Thus, the coadministration of DSG with OKT3 may be of clinical interest to reduce the humoral response triggered by the mAb.
强效免疫抑制剂鼠抗人CD3单克隆抗体OKT3的多次治疗有时会因主要由抗独特型抗体组成的中和性体液反应的出现而受到限制。仓鼠抗鼠CD3单克隆抗体145-2C11与OKT3具有许多共同特性,特别是在小鼠中诱导强烈抗体反应的能力。脱氧精胍菌素(DSG)是抗生素司帕沙星的一种代谢产物,已被证明在多种感染模型中以及针对常见抗原时可减少病原体引发的抗体产生。在本研究中,我们检测了DSG抑制145-2C11诱导的体液反应的能力。DSG以抗原特异性方式阻止抗CD3单克隆抗体引发的抗体产生,并显著降低先前用145-2C11致敏的小鼠的抗体产生。我们发现DSG对B细胞有长期作用,对T细胞有短暂作用。实际上,发现DSG可诱导B淋巴细胞产生长期的抗原特异性无反应性,并短暂降低T淋巴细胞向B细胞提供辅助的能力,部分原因是减少白细胞介素-4的产生。DSG并未降低抗CD3单克隆抗体的免疫抑制特性。事实上,与单独给予145-2C11或DSG相比,DSG与145-2C11联合使用可延长同种异体皮肤移植物的存活时间。因此,DSG与OKT3联合给药可能在临床上有助于减少单克隆抗体引发的体液反应。